Introduction
Among the rare non-albicans Candida species, Candida lusitaniae has emerged during the last 20 years as an important nosocomial pathogen. 1 From the first well documented case of infection in 1979, amphotericin B resistance has frequently been reported, in its different expressions: clinical resistance and microbiological (initial or acquired) resistance. 1 This has largely contributed to the distinguishing of C. lusitaniae from other Candida species. In 1997, we provided the first evaluation of its in vitro antifungal susceptibility pattern. 2 Since then, few studies have focused on this topic. [3] [4] [5] [6] To further determine the antifungal susceptibility pattern of C. lusitaniae, we report here the in vitro activities of four conventional systemic antifungal agents (amphotericin B, flucytosine, fluconazole and itraconazole) and of the new triazole voriconazole against a panel of clinical isolates, mostly colonizing ones. MICs were determined by the Etest, which is now well established as a reliable method for in vitro testing of antifungal agents, especially amphotericin B. 
Results and discussion
MICs for the quality control strains were always within the described limits (data not shown). 9 High MICs (1.5-2 mg/L and 3-12 mg/L for RPMI and AM3, respectively) were obtained for the amphotericin B-resistant reference strain, C. lusitaniae ATCC 200951. Table 1 summarizes the in vitro susceptibilities of 80 C. lusitaniae clinical isolates to fluconazole, itraconazole, voriconazole and flucytosine as determined by the Etest method. As shown, all the isolates were highly susceptible to fluconazole. Voriconazole was also very active in vitro. The susceptibility to itraconazole was good; only 4% of isolates had dose-dependent susceptibility (MICs 0.25-0.5 mg/L). These results confirm and extend those previously reported regarding the excellent activity of the triazoles against C. lusitaniae. 2, 3, 5 With regard to flucytosine, the MIC range was broad (0.004->32 mg/L). The distribution of MICs was clearly bimodal, with 81% of isolates inhibited at ≤4 mg/L and 19% of isolates not inhibited at 32 mg/L. Hence, the set included a significant percentage of flucytosine-resistant isolates. These results confirm and extend those of our previous study. 2 Among the rare studies that have addressed this issue recently, only a few reported, as we have, a high prevalence of isolates resistant to flucytosine (up to 50%). [3] [4] [5] [6] The substantial differences in susceptibility to flucytosine may be linked to the difference in the geographical origin of the isolates. This quite high level of resistance to flucytosine is important, since the drug is often used in combination with amphotericin B or with azoles as treatment for infection with this species. 1 Susceptibility to amphotericin B was investigated by using the two agar media that are relevant with the Etest, i.e. RPMI 1640 and AM3, both supplemented with 2% glucose. 5, 7 As shown, on both media, MIC ranges were broad and AM3 agar generated an upward shift of the MICs (Table 2) . A single isolate showed elevated MICs (0.75 and 4 mg/L on RPMI and AM3, respectively) and was clearly distinct from the other clinical isolates. It was thus easily categorized as resistant to amphotericin B with the interpretive breakpoints proposed above, i.e. ≥0.38 mg/L on RPMI 1640 and >1 mg/L on AM3. 5, 7 Note that the susceptibility status of this isolate has been confirmed by an analysis of the cell sterol composition. 10 As previously reported 7 with Etest on AM3, some C. lusitaniae isolates showed slightly elevated MICs (0.75-1 mg/L), and could have decreased susceptibility to amphotericin B. However, amphotericin B appeared very active in vitro against C. lusitaniae. These results confirm those of Pfaller et al., 5 who noted that primary resistance to amphotericin B was uncommon among incident isolates of C. lusitaniae. The amphotericin B susceptibility profile of the panel was further investigated by testing, for comparison, a set of C. albicans and C. glabrata colonizing isolates (Table 2 ). Like C. lusitaniae, C. glabrata has a haploid genome in which genetic alterations leading to resistance are more likely to be expressed than in diploid yeasts such as C. albicans. On RPMI 1640 agar, the in vitro susceptibility of C. lusitaniae to amphotericin B was similar to that of C. albicans, and C. lusitaniae appeared to be more susceptible to amphotericin B than C. glabrata ( Table 2 ). Note that, whatever the species, MICs yielded on RPMI 1640 agar were overall lower than those usually reported. 3, 6 This could reflect brand-to-brand variability of the agar medium, and prevented the establishment of a reliable interpretive breakpoint for Candida spp. and amphotericin B. On AM3, overall, the distributions of amphotericin B MICs were highly similar for the three species. However, C. lusitaniae appears to be slightly less susceptible to amphotericin B than the two other species. Its susceptibility level is closer to that of C. glabrata, for which amphotericin B resistance was clearly detected in two isolates, on AM3 as well as on RPMI.
Although the influence of both the test medium and the species makes it difficult to compare the levels of susceptibility to amphotericin B, it is obvious that C. lusitaniae is not as singular a species as was stated initially. 1 In conclusion, the present study expands the database of MICs for C. lusitaniae, making its antifungal susceptibility pattern more explicit. C. lusitaniae appears susceptible to amphotericin B, azole antifungal agents and, to a lesser extent, flucytosine. However, this issue should be further investigated by testing large panels of geographically diverse clinical isolates and, of course, with new antifungal agents. 
